QLS31903
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 21, 2023
A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients
(clinicaltrials.gov)
- P1 | N=150 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
Metastases • New P1 trial • Oncology • Solid Tumor • GPC3
1 to 1
Of
1
Go to page
1